Biomarkers for AD Alzheimer’s Disease

Posted by & filed under Part 28: NEUROGENETICS.

Bateman et al. performed a prospective, longitudinal study about Autosomal dominant Alzheimer’s disease. 128 participants went through baseline clinical and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests. Cross-sectional analyses of baseline data in relation to estimated years from expected symptom onset were conducted in order to determine the relative order and magnitude of pathophysiological changes.

Marker Timing with respect to symptoms onset
decline in CSF amyloid-beta (Aβ)42 25 years before expected symptom onset
Aβ deposition, as measured by PET 15 years
Increased CSF tau protein    15 years
Cerebral hypometabolism and impaired episodic memory 10 years
Global cognitive impairment, as measured by the Mini–Mental State Examination and the Clinical Dementia Rating scale 5 years

Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. Bateman et al. N Engl J Med. 2012 Aug 30;367(9):795-804. Epub 2012 Jul 11. PMID: 22784036

 Posted by Yannis Trakadis, MD

Leave a Reply

You must be logged in to post a comment.